穗蛋白
免疫逃逸
受体
单克隆抗体
免疫系统
糖基化
抗体
突变
结合位点
抗原抗体复合物
血浆蛋白结合
生物
2019年冠状病毒病(COVID-19)
分子生物学
化学
生物物理学
结晶学
遗传学
医学
生物化学
基因
传染病(医学专业)
疾病
病理
作者
Linjie Li,Kaiyuan Shi,Yuhang Gu,Zepeng Xu,Chang Shu,Dedong Li,Junqing Sun,Mengqing Cong,Xiaomei Li,Xin Zhao,Guanghui Yu,Songnian Hu,Hui Tan,Jianxun Qi,Xiaopeng Ma,Kefang Liu,George F. Gao
出处
期刊:Structure
[Elsevier BV]
日期:2024-07-15
卷期号:32 (8): 1055-1067.e6
被引量:15
标识
DOI:10.1016/j.str.2024.06.012
摘要
The recently emerged BA.2.86, JN.1, EG.5, EG.5.1, and HV.1 variants have a growth advantage. In this study, we explore the structural bases of receptor binding and immune evasion for the Omicron BA.2.86, JN.1, EG.5, EG.5.1, and HV.1 sub-variants. Our findings reveal that BA.2.86 exhibits strong receptor binding, whereas its JN.1 sub-lineage displays a decreased binding affinity to human ACE2 (hACE2). Through complex structure analyses, we observed that the reversion of R493Q in BA.2.86 receptor binding domain (RBD) plays a facilitating role in receptor binding, while the L455S substitution in JN.1 RBD restores optimal affinity. Furthermore, the structure of monoclonal antibody (mAb) S309 complexed with BA.2.86 RBD highlights the importance of the K356T mutation, which brings a new N-glycosylation motif, altering the binding pattern of mAbs belonging to RBD-5 represented by S309. These findings emphasize the importance of closely monitoring BA.2.86 and its sub-lineages to prevent another wave of SARS-CoV-2 infections.
科研通智能强力驱动
Strongly Powered by AbleSci AI